Objective-To analyse the potential association of the angiotensin converting enzyme (ACE) and angiotensin II type 1 receptor (ATIR) gene polymorphisms on left ventricular function and mass in patients with normal coronary arteries. Design-Consecutive sample. Setting-University hospital. Subjects-141 consecutive white patients referred for coronary angiography and with angiographically normal coronary arteries. Patients with valvar diseases, cardiomyopathies, or a history of myocardial infarction were excluded. Main outcome measures-Left ventricular variables were measured for all patients. The ACE and ATIR genotypes were determined with a polymerase chain reaction based protocol using DNA prepared from white blood cells. A general linear model was used to compare data according to the ACE and to the ATlR genotypes. Results-A strong association was observed between left ventricular mass and systemic hypertension (mean (SD) hypertension: 114 (31) g/m2; no hypertension 98 (23) glm2; P < 0.003). However, no influence of ACE and ATIR polymorphisms on left ventricular mass was found, regardless of systemic hypertension. The subjects homozygous for the ATIR CC mutation had a significantly lower ejection fraction than those with allele A (AC+AA) (mean (SD) 62(12)% and 68(10)%, respectively, P < 0.05). No synergistic interaction of ACE and ATlR gene polymorphisms on left ventricular function and mass was found. Conclusions-These data do not support an association of the ACE and ATIR genotypes on left ventricular hypertrophy in white patients with normal coronary arteries. (Heart 1997;77:502-505) 
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